{"brief_title": "Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections", "brief_summary": "This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters (CR-BSI). The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin.", "condition": ["Bacteremia"], "intervention_type": ["Drug"], "intervention_name": ["dalbavancin"], "criteria": "- The patient or his/her legally authorized representative has given informed consent by means approved by the investigator\u2019s IRB/EC; - > 18 years of age; - Had one or more central venous catheters at the time initial signs of infection were evident; - Creatinine clearance <50 mL/min; - Bilirubin > 2x the upper limit of normal; - Treatment with an antibiotic effective against Gram-positive bacterial infections for more than 24 hours within 48 hours of study medication initiation, - Prolonged antibiotic therapy for CR-BSI anticipated (i.e., >2 weeks)", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Bacteremia", "Vancomycin", "Dalbavancin", "Teicoplanin"], "id": "NCT00057369"}